This is the authors' abstract. We don't add key points for this paper.
BackgroundMeasurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are eligible for autologous stem-cell transplantation (ASCT) may be useful. MethodsIn this phase 3 trial, we randomly assigned transplantation-eligible patients with newly diagnosed myeloma who had completed induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) to receive consolidation therapy according to their MRD status. Patients who were MRD-negative at 10−5 sensitivity (i.e., <1 cancer cell per 100,000 normal cells, as assessed by next-generation sequencing) were assigned to undergo ASCT and receive Isa-KRd for two cycles (ASCT group) or to receive Isa-KRd for six cycles (Isa-KRd group). Patients who were MRD-positive at 10−5 sensitivity were assigned to undergo tandem ASCT (two ASCTs within a short period; tandem ASCT group) or to undergo ASCT and receive Isa-KRd for two cycles (single ASCT group). The primary end point was an MRD-negative status at 10−6 sensitivity before maintenance therapy. Research Summary Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma ResultsAmong 485 patients who were MRD-negative at 10−5 sensitivity after induction, a premaintenance MRD-negative status at 10−6 sensitivity occurred in 86% in the ASCT group and in 84% in the Isa-KRd group (adjusted relative risk, 1.02; 95% confidence interval [CI], 0.95 to 1.10; P=0.64). Among 233 patients who were MRD-positive at 10−5 sensitivity after induction, a premaintenance MRD-negative status at 10−6 sensitivity occurred in 32% in the tandem ASCT group and in 40% in the single ASCT group (adjusted relative risk, 0.82; 95% CI, 0.58 to 1.15; P=0.31); 15% of the patients in the tandem ASCT group did not undergo a second ASCT. During consolidation, disease progression occurred in 5 patients and death unrelated to disease progression occurred in 2 patients — all were in the Isa-KRd or tandem ASCT groups. No new safety signals were observed. The median follow-up was 16.8 months in the ASCT and Isa-KRd groups and 16.3 months in the tandem ASCT and single ASCT groups. ConclusionsAmong patients who were MRD-negative at 10−5 sensitivity after induction, the percentage with a premaintenance MRD-negative status at 10−6 sensitivity was not significantly higher with ASCT than with Isa-KRd. Among patients who were MRD-positive status at 10−5 sensitivity after induction, the percentage with a premaintenance MRD-negative status at 10−6 sensitivity was not significantly higher with tandem ASCT than with single ASCT. (Funded by Intergroupe Francophone du Myélome and others; MIDAS ClinicalTrials.gov number, NCT04934475.)
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Perrot et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: